Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HI 164

Drug Profile

HI 164

Alternative Names: HI-164N; HI-164OV

Latest Information Update: 24 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hunter Immunology
  • Developer Mariposa Health Limited
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Bronchitis; Otitis media; Sinusitis

Most Recent Events

  • 24 Jul 2015 Phase-II development for Chronic obstructive pulmonary disease (prevention of exacerbation) is ongoing in Australia
  • 30 Jun 2014 Mariposa Health Limited acquires Hunter Immunology
  • 29 Jun 2012 Final efficacy data from a phase IIb trial in Chronic obstructive pulmonary disease released by Bioxyne
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top